Asthma and irreversible airflow obstruction

PETER J BROWN, HUGH W GREVILLE, KEVIN E FINUCANE

From the Department of Pulmonary Physiology, Sir Charles Gairdner Hospital, Nedlands, Western Australia

ABSTRACT To determine whether asthma alone can cause irreversible airflow obstruction 42 men and 47 women with chronic asthma (mean duration 22 (SD 13) years) without evidence of other disease likely to cause irreversible airflow obstruction were treated with theophylline orally and a beta agonist both orally and by inhalation for four weeks. After two weeks of treatment the FEV₁ was less than 85% of the predicted normal value (%P) in 48 patients and these individuals then received prednisolone 0.6 mg/kg/day for two weeks. Duration and severity of asthma and smoking history were quantified by questionnaire; 38 patients were current smokers or ex-smokers. FEV₁ was measured at 0, 2, and 4 weeks. The mean difference between the best FEV₁ during the study and the predicted normal value was 0.29 l ($p < 0.001$); FEV₁ %P decreased with age ($r = -0.30$, $p < 0.01$) and with the duration ($r = -0.47$, $p < 0.001$) and severity ($r = -0.55$, $p < 0.001$) of asthma. Similar findings were noted when the results for non-smokers and those whose asthma started in adult life were analysed separately. We conclude that asthma alone can cause irreversible airflow obstruction and that the degree of obstruction is a function of the duration and severity of previous asthma. The results suggest the possibility that irreversible airflow obstruction in asthma may be preventable by minimising the degree of persistent asthma.

Evidence from several studies suggests that chronic asthma may be associated with the development of irreversible airflow obstruction. Firstly, pulmonary function is frequently abnormal during clinical remission from asthma;¹⁻⁷ secondly, the airways of patients with chronic asthma dying from non-respiratory causes show changes including mucous plugging, chronic inflammatory and eosinophilic infiltration, basement membrane thickening, and smooth muscle hypertrophy,^{8,9} which could cause persistent narrowing; and, thirdly, many patients with asthma by definition have persistent airflow obstruction, which is not reversed by intensive treatment including corticosteroids.^{10,11} Despite this evidence, a relationship between asthma and irreversible airflow obstruction has not been firmly established because there has been no large scale study of ventilatory function in patients with asthma in which reversible obstruction has been minimised by intensive treatment and in which other conditions likely to cause irreversible obstruction, such as emphysema, cigarette smoking, and occupational

airway disease, have been either considered or excluded. This paper reports such a study, the aims of which were to determine whether asthma alone can cause irreversible airflow obstruction and whether factors such as cigarette smoking, age of onset of asthma, and duration and severity of previous asthma were associated with any irreversible obstruction.

Patients and methods

One hundred patients with asthma of more than three years' duration who were attending outpatient clinics of the department of respiratory medicine at the Sir Charles Gairdner Hospital were studied. The patients had a clinical diagnosis of asthma with variability in the FEV₁ of at least 20% within a period of six months before the study; 70% showed marked variation of FEV₁ with changes of over 50% in this period. The patients had no clinical or radiographic evidence of bronchiectasis, pulmonary eosinophilia, allergic bronchopulmonary aspergillosis, or emphysema. Gas transfer, measured on admission to the study by the single breath carbon monoxide technique, was normal in all. Patients thought to have an occupational cause for their asthma or a history of environmental exposure likely to cause chronic bronchitis and those in whom oral cortico-

Address for reprint requests: Dr KE Finucane, Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009.

Accepted 25 August 1983

steroid treatment was contraindicated were excluded from the study.

All patients received inhaled and oral beta agonists (salbutamol 200 μ g four hourly and 4 mg three times daily) and oral theophylline (125 mg four times daily) for a minimum of four weeks. Two weeks after commencing this treatment 48 patients in whom the postbronchodilator FEV₁ was less than 85% of the predicted normal value (%P) received additional treatment with prednisolone 0.3 mg per kg twice daily (dosage range 35–55 mg/day) for a minimum of two weeks. Inhaled corticosteroids or cromoglycate or both were continued in the 40 patients being treated with these drugs on admission to the study. Plasma theophylline concentrations were measured after two weeks' treatment in 35 randomly selected patients to ensure that the concentration was in the therapeutic range of 55–110 μ mol/l. Seven patients who developed intercurrent asthma during the study continued treatment until the FEV₁ value had returned at least to the level found before deterioration. FEV₁ was measured with a calibrated electronic spirometer (Monaghan M403) on entry to the study and after two and four weeks of treatment; the FEV₁ was taken as the highest value from three forced vital capacity readings in which the FEV₁ varied by 3% or less. Values were corrected to BTPS. All measurements were made after inhalation of an aerosol of isoprenaline sulphate, 200–300 μ g, between 1400 and 1500 hours.

Patients completed a modified Medical Research Council questionnaire on respiratory symptoms (1966) to ascertain smoking history, presence of cough and sputum, and duration and severity of asthma. A score representing the severity of asthma, similar to that used by others,^{12,13} was obtained by summing the scores from each of the following: (1) frequency and persistence of "usual" wheezing multiplied by the duration in years of these symptoms (7 grades, maximum score 450*); (2) impairment of daily activities (7 grades, maximum 70 points); (3) hospital admissions and loss of time from school and work due to asthma (maximum 200 points*); (4) usual medication multiplied by the number of years taken (maximum 300 points*); (5) patients' assessment of severity of asthma on a self-rating scale (100 points). Scores greater than 300 indicated asthma of considerable clinical severity with a high incidence of persistent wheeze, effort dyspnoea, and hospital admission.

The highest FEV₁ for each individual during the study was compared with the predicted normal value derived from the data of Knudson *et al*¹⁴ and

Burrows *et al*¹⁵ and based on age, sex, height, and cigarette smoking. Use of these data to predict the FEV₁ of an Australian population, however, could be inappropriate. We therefore also compared the highest FEV₁ of asthmatic subjects who had never smoked with that predicted from FEV₁ data obtained during the 1972 Busselton (W Australia) population survey on 514 men and 1024 women over 18 years of age who had never smoked and had no history of lung or heart disease¹⁶ (also N Stenhouse, personal communication); data on symptom free Australian smokers were not available for comparison. The relationships between FEV₁ and age, age at onset and duration of asthma, the score for severity of asthma, cigarette consumption, and chronic cough and sputum were examined by linear regression and multiple regression analyses. Differences in these relationships between subgroups were examined by comparison of regression lines.¹⁷

Results

Eighty nine of the 100 patients completed the study; 10 did not attend for review appointments and one patient withdrew because of tremor induced by salbutamol. Tremor caused 22 patients to discontinue oral salbutamol; in 12 of them terbutaline, 5 mg three times a day, was successfully substituted. Ten patients discontinued theophylline because of gastrointestinal side effects. All patients treated with prednisolone completed two weeks of treatment; no adverse effects were noted. Table 1 summarises the principal characteristics of the 89 patients who completed the study. Table 2 summarises the response to treatment. The mean FEV₁ increased with treatment in the entire group ($p < 0.001$) and in both those treated with steroids ($p < 0.001$) and those not treated with steroids ($p < 0.001$); in the latter group the mean FEV₁ on completion of treatment was not significantly different from the predicted normal value.

The mean difference between the predicted normal FEV₁ and the highest value observed during treatment was 0.29 l ($p < 0.001$). The highest FEV₁ %P decreased with increasing age ($r = -0.26$, $p < 0.05$) and with increasing duration (fig 1) and severity (fig 2) of previous asthma. The highest FEV₁ observed during the 12 months before conclusion of the study was also significantly less than predicted (mean difference 0.24 l, $p < 0.01$) and highly correlated ($p < 0.001$) with both the duration and the severity of asthma ($r = -0.48$ and -0.56 respectively). Similar results were obtained in 47 of the patients whose asthma had started after their 16th birthday (adult onset asthma) and in the 51 patients

*Maxima quoted were the highest scores obtained.

Table 1 Principal characteristics of patients

	No of patients	Height (cm)*	Age (y)*	Asthma		Smoking history		Chronic cough and sputum‡
				Age at onset (y)*	Duration (y)*	Number†	Pack years*	
Male	42	173.5 (6.1)	43.0 (14.9)	23.4 (19.2)	20.6 (14.2)	27 (8C, 19E)	21.8 (15.1)	19 [5]
Female	47	162.1 (6.0)	41.4 (13.8)	17.9 (15.6)	23.4 (11.5)	11 (4C, 7E)	8.1 (7.7)	13 [8]
Total	89	167.5 (8.3)	42.2 (14.3)	20.5 (17.5)	22.1 (12.9)	38 (12C, 26E)	17.9 (14.7)	32 [13]
Male-female differences		p < 0.001	NS	NS	NS		p < 0.01	

*Mean values with standard deviations in parentheses.

†Includes number of current smokers (C) and ex-smokers (E).

‡Number with cough and sputum who had never smoked in square brackets.

NS—not significant.

Table 2 FEV₁ before and during treatment as percentage of predicted normal values^{14 15} (means with standard deviations in parentheses)

	Initial	After 2 weeks' treatment	After 4 weeks' treatment	Best in study	Best in previous year
All patients (n = 89)	77.3 (24.0)	79.1 (25.1)	87.9 (23.1)	89.9 (22.7)	91.6 (22.6)
No steroids (n = 41)	96.8 (13.9)	101.2 (11.0)	104.3 (12.7)	106.7 (11.8)	108.3 (11.7)
Steroids (n = 48)	60.5 (17.1)	60.1 (17.3)	73.9 (20.7)	75.6 (19.6)	77.4 (19.8)

who had never smoked (table 3). In those who had never smoked the mean difference between the highest observed and the predicted normal FEV₁ and the relationship between FEV₁ and duration and severity of asthma were similar whether the data of Knudson *et al*¹⁴ or of the Busselton population

survey¹⁶ were used to predict FEV₁ (table 3). The decrease of FEV₁ %P with age and with the duration and severity of asthma was not significantly different between smokers and those who had never smoked, between those with childhood onset of asthma and those with adult onset, or between those with and those without chronic cough and sputum. Women showed a greater decrease of FEV₁ %P with age than males (p < 0.05); but the decreases associated with increasing duration and with increasing severity of asthma were similar in men and women.

There were no significant correlations between age and duration or age and severity of asthma, between duration and self-assessment of asthma severity or between FEV₁ %P and age of onset of asthma, or between FEV₁ %P and smoking history, either for all subjects or men and women separately. The mean severity score was significantly higher (p < 0.01) in women (317 ± 148) than in men (235 (SD 144)). FEV₁ %P was significantly correlated (p < 0.01 or < 0.001) with the score for impairment of daily activities (r = -0.33), hospital admissions (r = -0.31), the patients' self-assessment of asthma severity (r = -0.29), usual medication requirements (r = -0.42), and duration and severity of wheeze (r = -0.43). Total severity score and the patients' self-assessment of the severity of asthma were highly correlated (r = 0.56, p < 0.001).

Fig 1 Relationship between duration of asthma and the highest FEV₁ (percentage of predicted value) during treatment in each of the 89 patients completing at least four weeks' treatment.

Discussion

The results of this study suggest that asthma alone can cause irreversible airflow obstruction and that

Fig 2 Relationship between total score for severity of asthma in arbitrary units and the highest FEV₁ (percentage of predicted value) during treatment.

the degree of obstruction is a function of the duration and severity of previous asthma. The validity of these conclusions depends on the way in which any persistent reversible airflow obstruction affected the results, the suitability of the data used to predict normal values, and the accuracy of our assessment of the severity of asthma. In any group of patients with chronic asthma a proportion will have diurnal fluctuations in airway function which are not abolished by treatment,^{18,19} while others may develop intercurrent exacerbations. Several factors suggest that any persistent reversible obstruction in our patients was small and not responsible for the results: (1) The dose and duration of steroid treat-

ment were sufficient to define corticosteroid responsiveness.²⁰ (2) Patients in the group which did not receive steroids achieved a normal FEV₁. (3) The highest FEV₁ during the study was little different from the highest value during the previous 12 months (mean difference 0.05 l) and use of this latter value in analysing the results did not alter the findings. (4) The effect of diurnal variation of FEV₁ was minimised by the study protocol. (5) Only seven patients developed symptomatic asthma during the study; in these treatment was prolonged and in five the final FEV₁ was greater than the best FEV₁ in the preceding 12 months. (6) It is unlikely that any reversible component of airflow obstruction would have been systematically greater in older people and in those with the longer duration of asthma, particularly as age and duration of asthma were not correlated with each other or with the patients' assessment of the severity of asthma.

We used the data of Knudson *et al*¹⁴ and Burrows *et al*¹⁵ to predict the FEV₁ of the healthy population because these studies included large numbers and took account of the effect of cigarette smoking. It is unlikely that use of these data resulted in overestimation of the difference between the FEV₁ of asthmatics and healthy people or of the effect of age and duration of asthma on FEV₁. In the asthmatics who had never smoked comparison of the FEV₁ with the data of Knudson *et al* and with that of a local healthy population gave identical results, while the decline of FEV₁ with age found by Knudson *et al* and Burrows *et al* was similar to that observed in four other studies.²¹⁻²⁴

Table 3 Difference between highest FEV₁ during treatment and predicted normal value and relationship between FEV₁ (% predicted) and duration and severity of asthma

	All patients	Adult onset	Never smoked
Number	89	47	51
FEV ₁ P-FEV ₁ H: mean difference (l)	0.29§	0.22†	0.42§ (0.46§)*
FEV ₁ H as %P v duration of asthma (r)	-0.47§	-0.44‡	-0.42 (-0.42)*
FEV ₁ H as %P v severity of asthma (r)	-0.55§	-0.56§	-0.55§ (-0.51§)*

* Analysis based on FEV₁ predicted from Busselton population survey.¹⁶

Significance of differences and correlations: † p < 0.05; ‡ p < 0.01; § p < 0.001.

P—predicted; H—highest value during treatment.

Methods of estimating the severity of previous asthma are necessarily imprecise because they depend largely on subjective criteria and on the weighting applied to these criteria by the investigators. Nevertheless, in this study the factors used to quantitate severity, except for loss of time from work, bore a consistent relationship to the highest FEV₁ during treatment and were internally consistent with the patients' assessment of the severity of their asthma.

Some support for the suggestion that asthma alone can cause irreversible airflow obstruction comes from previous studies of airway function during remission from asthma even though these were not designed to examine this question.^{4,5,7,25} Loren *et al* reported three children with severe asthma and an irreversible component of airflow obstruction despite intensive treatment with bronchodilators and prednisolone.¹⁰

Factors which may contribute to the development of irreversible airflow obstruction include cigarette smoking and respiratory illness in childhood.²⁶ Our results in lifelong non-smokers and in those whose asthma started after the age of 15 years showed that the development of irreversible obstruction in asthma is not dependent on smoking or on a childhood onset of asthma. Furthermore, neither these factors nor chronic cough and sputum appear to influence the degree of airflow obstruction.

The observation that the women in this study had a significantly greater decline of FEV₁ with age than men, but no difference in the severity of asthma as a function of age or duration of disease, suggests a possible sex related difference in the degree of irreversible obstruction that is independent of the severity of asthma. The strong relationship between the degree of airflow obstruction and the duration and severity of asthma, which together accounted for 37% of the variability in FEV₁ %P, suggests that chronic poorly controlled asthma causes irreversible narrowing of airways and raises the possibility that improved control of asthma may prevent irreversible obstruction. The findings therefore provide some support for recent suggestions that one of the aims of treatment in chronic asthma should be to maintain airway function as near normal as practicable.²⁷ The extent to which the conclusions of our study apply to the general population of patients with asthma cannot be stated. There is, however, a high incidence of airflow obstruction in non-hospital patients with asthma;^{6,28} if persistent asthma can cause irreversible obstruction then the implications are general.

This study was supported by the Asthma Foundation of Western Australia. We thank Associate Pro-

fessor N Stenhouse for access to data from the Busselton Population Survey and help with data analysis, Dr GF Ryan and Professor JW Paterson, who reviewed an earlier version of the manuscript, and Drs AW Musk, JL Elder, AR Adams, and AE Tribe for access to patients under their care.

References

- 1 Beale HD, Fowler WS, Comroe JH. Pulmonary function in 20 asthmatic patients in the symptom-free interval. *J Allergy Clin Immunol* 1952;**23**:1-10.
- 2 Gold WM, Kaufman HS, Nadel JA. Elastic recoil of the lungs in chronic asthmatic patients before and after therapy. *J Appl Physiol* 1967;**23**:433-8.
- 3 Finucane KE, Colebatch HJH. Elastic behaviour of the lungs in patients with airway obstruction. *J Appl Physiol* 1969;**26**:330-8.
- 4 Cade JF, Pain MCF. Pulmonary function during clinical remission of asthma. *Aust NZ J Med* 1973;**iii**:545-51.
- 5 Palmer KNV, Kelman GR. Pulmonary function in asthmatic patients in remission. *Br Med J* 1975;**i**:485-6.
- 6 Sobol BJ, Emirgil C. Pulmonary function in ambulatory asthmatics. *J Chron Dis* 1976;**29**:233-42.
- 7 McCarthy DS, Sigurdson M. Lung elastic recoil and reduced airflow in clinically stable asthma. *Thorax* 1980;**35**:298-302.
- 8 Dunnill MS. The pathology of asthma. In: *Transactions of the World Asthma Conference*. London: The Chest and Heart Association, 1965:23-7.
- 9 Glynn AA, Michaels L. Bronchial biopsy in chronic bronchitis and asthma. *Thorax* 1960;**15**:142-51.
- 10 Loren ML, Leung PK, Cooley RL, Chai H, Bell TD, Buck VM. Irreversibility of obstructive changes in severe asthma in childhood. *Chest* 1978;**74**:126-9.
- 11 Carmichael J, Paterson IC, Diaz P, Crompton GK, Kay AB, Grant IWB. Corticosteroid resistance in chronic asthma. *Br Med J* 1981;**282**:1419-22.
- 12 Mansmann HC. The evolution and modification of intractable bronchial asthma. In: Johnson RF, ed. *Pulmonary care*. New York: Grune and Stratton, 1973:165-79.
- 13 Rubinfeld AR, Pain MCF. Relationship between bronchial reactivity, airway caliber, and severity of asthma. *Am Rev Respir Dis* 1977;**115**:381-7.
- 14 Knudson RJ, Slatin RC, Lebowitz MD, Burrows B. The maximum expiratory flow volume curve: normal standards, variability and effects of age. *Am Rev Respir Dis* 1976;**113**:587-600.
- 15 Burrows B, Knudson RJ, Cline MG, Lebowitz MD. Quantitative relationships between cigarette smoking and ventilatory function. *Am Rev Respir Dis* 1977;**115**:195-205.
- 16 Stenhouse NS. *Busselton norms. Statistics of the physiological variables measured at the Busselton Health Survey 1972*. Perth: University of W Australia Press, 1979.
- 17 Armitage P. *Statistical methods in medical research*. Oxford: Blackwell Scientific Publications, 1974:279-301.
- 18 Hetzel MR, Clark TJH, Houston K. Physiological pat-

- terns in early morning asthma. *Thorax* 1977;**32**:418–23.
- ¹⁹ Souter CA, Costello J, Ijaduola O, Turner-Warwick M. Nocturnal and morning asthma: relationship to plasma corticosteroids and response to cortisol infusion. *Thorax* 1975;**30**:436–40.
 - ²⁰ Webb J, Clark TJH, Chilvers C. Time course of response to prednisolone in chronic airflow obstruction. *Thorax* 1981;**36**:18–21.
 - ²¹ Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. *Am Rev Respir Dis* 1981;**123**:659–64.
 - ²² Cherniack RM, Raber MB. Normal standards for ventilatory function using an automated wedge spirometer. *Am Rev Respir Dis* 1972;**106**:38–46.
 - ²³ Morris JF, Koski A, Johnson LC. Spirometric standards for healthy nonsmoking adults. *Am Rev Respir Dis* 1971;**103**:57–67.
 - ²⁴ Schoenberg JB, Beck GJ, Bouhuys A. Growth and decay of pulmonary function in healthy blacks and whites. *Respir Physiol* 1978;**33**:367–93.
 - ²⁵ Irnell L. A study of bronchial asthma. *Acta Med Scand* 1964;**176**, Suppl 419:1–170.
 - ²⁶ Burrows B, Knudson RJ, Lebowitz MD. The relationship of childhood respiratory illness to adult obstructive airway disease. *Am Rev Respir Dis* 1977;**115**:751–60.
 - ²⁷ Woolcock AJ. Inhaled drugs in the prevention of asthma. *Am Rev Respir Dis* 1977;**115**:191–4.
 - ²⁸ Martin AJ, McLennan LA, Landau LI, Phelan PD. The natural history of childhood asthma to adult life. *Br Med J* 1980;i:1397–400.